首页> 美国卫生研究院文献>other >Low Prevalence of Cfr-Mediated Linezolid Resistance among Methicillin-Resistant Staphylococcus aureus in a Spanish Hospital: Case Report on Linezolid Resistance Acquired during Linezolid Therapy
【2h】

Low Prevalence of Cfr-Mediated Linezolid Resistance among Methicillin-Resistant Staphylococcus aureus in a Spanish Hospital: Case Report on Linezolid Resistance Acquired during Linezolid Therapy

机译:其中CFR介导的利奈唑胺耐药性低流行耐甲氧西林金黄色葡萄球菌在西班牙医院:利奈唑胺治疗期间利奈唑胺耐药获得性病例报告

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Linezolid is an effective antimicrobial agent to treat methicillin-resistant Staphylococcus aureus (MRSA). Resistance to linezolid due to the cfr gene is described worldwide. The present study aimed to analyze the prevalence of the cfr–mediated linezolid resistance among MRSA clinical isolates in our area. A very low prevalence of cfr mediated linezolid resistance was found: only one bacteremic isolate out of 2 215 screened isolates. The only linezolid resistant isolate arose in a patient, previously colonized by MRSA, following linezolid therapy. Despite the low rate of resistance in our area, ongoing surveillance is advisable to avoid the spread of linezolid resistance.
机译:利奈唑胺是治疗耐甲氧西林的金黄色葡萄球菌(MRSA)的有效抗菌剂。全世界都描述了由于cfr基因对利奈唑胺的抗药性。本研究旨在分析我们地区MRSA临床分离株中cfr介导的利奈唑胺耐药性的患病率。发现cfr介导的利奈唑胺耐药性的患病率很低:在筛选的2 215个分离株中,只有一个细菌分离株。利奈唑胺治疗后,患者中出现了唯一对利奈唑胺耐药的分离株,该患者先前已被MRSA定植。尽管我们地区的耐药率较低,但建议进行持续监测以避免利奈唑胺耐药性的扩散。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号